New Delhi: Brokerage firms Institutional Research and Elara Capital have initiated Buy rating on shares of SBI Life Insurance Company. The brokerages backed the insurance firm after the latter declared Q4 2025-26 Results. SBI Life share price was at Rs 1,827.50 at the time of writing this article on Thursday.
SBI Life Insurance details on BSE as of 23 April 2026
Previous Close: 1884.75
Open: 1874.10
High: 1886.10
Low: 1808.80
VWAP: 1,854.33
52 Wk High: 2,132.90
52 Wk Low: 1,601.65
Upper Price Band: 2,073.20
Lower Price Band: 1,696.30
Price Band: No Band
TTQ (Lakh): 1.21
Turnover (Cr.): 22.36
2W Avg Qty`(Lakh): 0.58
Mcap Full (Cr.): 1,83,385.30
Mcap FF (Cr.): 81,849.08
SBI Life Insurance Company declared its January-March FY26 quarter results and posted a marginal drop in profit to Rs 805 crore. The insurer had posted a net profit of Rs 814 crore in the same quarter of 2024-25. The income during the last quarter of FY26 went down to Rs 5,658 crore as compared to Rs 24,169 crore in the year-ago financial year (FY25).
SBI Life Insurance share price target
Institutional Research stated that SBI Life Insurance reported a 13% year-on-year growth in APE and a 14% growth in VNB in FY26. However, the figures were slightly lower than expected. The geopolitical tensions impacted insurer’s business growth in Q4 FY26.
The brokerage revised its APE and VNB growth estimates to a CAGR of approximately 14 to 15 percent between FY26 and FY28. The brokerage believes that the company is valued at approximately 2.1 times based on its FY28 estimated EV. Initiating a Buy rating on SBI Life Insurance stocks, the brokerage gave a share target price of Rs 2,400.
Buy rating on SBI Life Insurance
Elara Capital’s advised market players to pump in money to buy shares of SBI Life Insurance and set a share price target of Rs 2,510. On Thursday, the stock has trading with over 3 per cent loss. Over the past six months, it has declined by approximately 1.30 per cent. However, over the past year, the counter appreciated around 14 per cent.
(Disclaimer: This article is only meant to provide information. News9 does not recommend buying or selling shares or subscriptions of any IPO)